1. Homepage
  2. Equities
  3. China
  4. Shanghai Stock Exchange
  5. Zhejiang Jiuzhou Pharmaceutical Co., Ltd
  6. Summary
    603456   CNE100001W36

ZHEJIANG JIUZHOU PHARMACEUTICAL CO., LTD

(603456)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   End-of-day quote. End-of-day quote Shanghai Stock Exchange
05/11/2022 05/12/2022 05/13/2022 05/16/2022 05/17/2022 Date
50.64 50.9 50.53 49.79 49.72 Last
6920369 6532141 8883877 4328135 3682096 Volume
+1.38% +0.51% -0.73% -1.46% -0.14% Change
Estimated financial data (e)
Sales 2022 5 431 M 806 M 806 M
Net income 2022 893 M 133 M 133 M
Net Debt 2022 - - -
P/E ratio 2022 46,4x
Yield 2022 0,70%
Sales 2023 6 989 M 1 037 M 1 037 M
Net income 2023 1 173 M 174 M 174 M
Net Debt 2023 - - -
P/E ratio 2023 35,3x
Yield 2023 0,96%
Capitalization 41 484 M 6 115 M 6 157 M
Capi. / Sales 2022 7,64x
Capi. / Sales 2023 5,94x
Nbr of Employees 4 083
Free-Float 52,2%
More Financials
Company
Zhejiang Jiuzhou Pharmaceutical Co.,Ltd. is a China-based company principally engaged in the research, development, production and sales of chemical Active Pharmaceutical Ingredients (API) and intermediates. The Company mainly operates through two segments, including the New Drug and Intermediates Contract Development and Manufacturing Organization (CDMO) segment and the Specialty APIs and Intermediates segment. The... 
Sector
Specialty Chemicals
Calendar
05/24 | 02:00amShareholder meeting
More about the company
Ratings of Zhejiang Jiuzhou Pharmaceutical Co., Ltd
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
D
More Ratings
All news about ZHEJIANG JIUZHOU PHARMACEUTICAL CO., LTD
04/19Zhejiang Jiuzhou Pharmaceutical Co., Ltd Reports Earnings Results for the First Quarter..
CI
03/21Chinese Shares Extend Gains; Four Drugmakers Rally on Pfizer Deal
MT
03/20Fosun Pharma, Huahai, Three Other Chinese Firms to Produce Ingredients For Pfizer&rsquo..
MT
01/04Zhejiang Jiuzhou Pharmaceutical Co., Ltd signed Investment Agreement to acquire a 25.8%..
CI
2021Nan Jing Kang Chuan Ji Pharmatech Co., Ltd. announced that it expects to receive CNY 80..
CI
2021Zhejiang Siwei Pharmaceutical Technology Co., Ltd announced that it has received CNY 30..
CI
2021Zhejiang Jiuzhou Pharmaceutical Co., Ltd completed the acquisition of Teva Pharmaceutic..
CI
2021Zhejiang Jiuzhou Pharmaceutical Co., Ltd signed a Equity Transfer Agreement to acquire ..
CI
2021Zhejiang Jiuzhou Pharmaceutical Co., Ltd Reports Earnings Results for the Nine Months E..
CI
2021Zhejiang Siwei Pharmaceutical Technology Co., Ltd announced that it expects to receive ..
CI
2021ZHEJIANG JIUZHOU PHARMACEUTICAL CO., : 603456) added to FTSE All-World Index
CI
2021ZHEJIANG JIUZHOU PHARMACEUTICAL CO., : 603456) added to S&P Global BMI Index
CI
2021Zhejiang Jiuzhou Pharmaceutical Co., Ltd Reports Earnings Results for the Half Year End..
CI
2021Zhejiang Jiuzhou Pharmaceutical Co., Ltd Reports Earnings Results for the First Quarter..
CI
2021Ruibo Pharmaceutical Co., Ltd. announced that it has received CNY 280 million in fundin..
CI
More news
News in other languages on ZHEJIANG JIUZHOU PHARMACEUTICAL CO., LTD
04/19Zhejiang Jiuzhou Pharmaceutical Co., Ltd. annonce ses résultats financiers pour le prem..
03/21Les actions chinoises prolongent leurs gains ; quatre fabricants de médicaments se rall..
03/20Fosun Pharma, Huahai et trois autres entreprises chinoises vont produire des ingrédient..
2020Zhejiang Jiuzhou Pharmaceutical Co., Ltd annonce un dividende en espèces pour l'année 2..
2020Borsa Shanghai in ribasso su aumento tensioni Usa-Cina, timori economici
More news
Chart ZHEJIANG JIUZHOU PHARMACEUTICAL CO., LTD
Duration : Period :
Zhejiang Jiuzhou Pharmaceutical Co., Ltd Technical Analysis Chart | 603456 | CNE100001W36 | MarketScreener
Technical analysis trends ZHEJIANG JIUZHOU PHARMACEUTICAL CO., LTD
Short TermMid-TermLong Term
TrendsBullishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 5
Last Close Price 49,72 CNY
Average target price 63,18 CNY
Spread / Average Target 27,1%
EPS Revisions
Managers and Directors
Zhi Hong Chen General Manager & Director
Yu Jie Sha Chief Financial Officer
Li Rong Hua Chairman
Meng Sheng Sun Chairman-Supervisory Board
Yuan Qiang Li Director-Technology, Research & Development